Last reviewed · How we verify
NCT06973382: EPRQoL-PAH
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
NA trial testing Comprehensive Pulmonary Rehabilitation Program in PAH in 84 participants. Not yet recruiting.
31 October 2027
Quick facts
| Lead sponsor | Beijing Chao Yang Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 84 |
| Start date | 20 May 2025 |
| Primary completion | 31 October 2027 |
| Estimated completion | 31 October 2027 |
Drugs / interventions tested
- Comprehensive Pulmonary Rehabilitation Program
- Standard Pulmonary Rehabilitation
Conditions studied
Sponsor
Beijing Chao Yang Hospital
Who can join
18 and older, any sex, with PAH or CTEPH. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06973382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Chao Yang Hospital trials
Trials by the same sponsor.
- NCT07520305 — Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes · NA · not yet recruiting
- NCT07490925 — Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS · NA · not yet recruiting
- NCT07382986 — IMPACT COPD Cohort (China) · recruiting
- NCT07323134 — The Effect of Semaglutide on the Intestinal Flora in Obesity · not yet recruiting
- NCT07049692 — Hyperbaric Oxygen After Stroke Thrombectomy: A Multicenter Randomized Trial on Safety and Efficacy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06973382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Chao Yang Hospital
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06973382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing